Coronavirus disease (COVID-19) pandemic has a tremendous effect on people’s lives worldwide, and the number of infected patients increases daily. The healthcare sector is affected by a large number of patients with COVID-19, and a solution is urgently needed to avert the risk of deteriorating patients in terms of prioritizing patients based on their health conditions. Prioritization of patients with COVID-19 is a complex and multi-criteria decision-analysis (MCDA) problem due to (i) multiple biological laboratory examination criteria, (ii) criteria importance and (iii) trade-off amongst the criteria. This study presents a new multi-biological laboratory examination framework for prioritizing patients with COVID-19 on the basis of integrated MCDA methods. The experiment was conducted on the basis of three phases. In the first phase, patient datasets containing eight biological laboratory examination criteria for six patients with COVID-19 were derived and discussed. The outcome of this phase was used to propose a decision matrix on the basis of the intersection between “biological laboratory examination criteria” and “COVID-19 patients list”. In the second phase, the analytic hierarchy process (AHP) method was utilized to set the subjective weights for the biological laboratory examination criteria by respiratory experts. In the last phase, the VIekriterijumsko KOmpromisno Rangiranje (VIKOR) method was adopted to prioritize patients in the context of individual and group decision making (GDM). Results showed that (1) the integration of AHP–VIKOR method based on individual and GDM contexts was effective for solving prioritization problems for patients with COVID-19, and (2) the prioritization results of patients with COVID-19 showed no variation in the internal and external VIKOR GDM contexts. The proposed multi-biological laboratory examination framework can differentiate between the mild and serious or critical condition of patients with COVID-19 by prioritizing them based on integrated AHP–VIKOR methods. In conclusion, medical sectors can use the proposed framework to differentiate the health conditions of infected patients and to assign appropriate care with prompt and effective treatment.

中文翻译：

---

基于综合 AHP 和组 VIKOR 方法对 COVID-19 患者进行优先排序的多生物实验室检查框架

冠状病毒病 (COVID-19) 大流行对全世界人们的生活产生了巨大影响，受感染的患者人数每天都在增加。医疗保健部门受到大量 COVID-19 患者的影响，迫切需要一种解决方案，以根据患者的健康状况对患者进行优先排序，从而避免患者病情恶化的风险。由于（i）多个生物实验室检查标准，（ii）标准重要性和（iii）标准之间的权衡，COVID-19患者的优先级是一个复杂的多标准决策分析（MCDA）问题。本研究提出了一种新的多生物实验室检查框架，用于在综合 MCDA 方法的基础上对 COVID-19 患者进行优先排序。实验分三个阶段进行。在第一阶段，导出并讨论了包含六名 COVID-19 患者的八项生物实验室检查标准的患者数据集。该阶段的结果用于根据“生物实验室检查标准”和“COVID-19 患者名单”之间的交叉点提出决策矩阵。在第二阶段，采用层次分析法（AHP）方法设置呼吸专家生物实验室检查标准的主观权重。在最后一个阶段，采用 VIKriterijumsko KOmpromisno Rangiranje (VIKOR) 方法在个人和群体决策 (GDM) 的背景下优先考虑患者。结果表明（1）基于个体和 GDM 上下文的 AHP-VIKOR 方法的整合对于解决 COVID-19 患者的优先级问题是有效的，(2) COVID-19 患者的优先排序结果显示，在内部和外部 VIKOR GDM 环境中没有变化。拟议的多生物实验室检查框架可以通过基于综合 AHP-VIKOR 方法的优先级来区分 COVID-19 患者的轻度和严重或危重情况。总之，医疗部门可以使用建议的框架来区分受感染患者的健康状况，并分配适当的护理和及时有效的治疗。拟议的多生物实验室检查框架可以通过基于综合 AHP-VIKOR 方法的优先级来区分 COVID-19 患者的轻度和严重或危重情况。总之，医疗部门可以使用建议的框架来区分受感染患者的健康状况，并分配适当的护理和及时有效的治疗。拟议的多生物实验室检查框架可以通过基于综合 AHP-VIKOR 方法的优先级来区分 COVID-19 患者的轻度和严重或危重情况。总之，医疗部门可以使用建议的框架来区分受感染患者的健康状况，并分配适当的护理和及时有效的治疗。